Article Text

Download PDFPDF
Let’s add in some clindamycin

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Clindamycin seems to be being used more frequently (just an anecdotal observation). The Archivist has always held clindamycin in reserve for careful use as an adjuvant to using β-lactam antibiotics for the more severe group A β-haemolytic streptococcal invasive infections (iGAS) such as necrotising fasciitis. Is there good evidence of a benefit in the use of clindamycin in treating patients with invasive non-group A/B β-haemolytic streptococcal (iNABS) infections? Babiker A et al. [Lancet Infectious Dis 2021 S1473-3099(20)30523-5] have published the findings of a retrospective multicentre cohort study, using a dataset from adult patients in an …

View Full Text


  • Provenance and peer review Commissioned; internally peer reviewed.